Microbial Ecology in Health and Disease

Synbiotic-associated improvement in liver function in cirrhotic patients: Relation to changes in circulating cytokine messenger RNA and protein levels

Stephen M. Riordan a, Narelle A. Skinner b, Christopher J. McIver c, Qing Liu a, Stig Bengmark d, David Bihari e, Kumar Visvanathan b

a Gastrointestinal and Liver Unit, Prince of Wales Hospital and University of New South Wales, Sydney, Australia
b Department of Infectious Diseases, Monash Medical Centre and Monash University, Melbourne, Australia
c Department of Microbiology, Prince of Wales Hospital and University of New South Wales, Sydney, Australia
d Institute of Hepatology, University College London, UK
e Department of Intensive Care, Prince of Wales Hospital and University of New South Wales, Sydney, Australia

Online Publication Date: 01 January 2007

To cite this Article: Riordan, Stephen M., Skinner, Narelle A., McIver, Christopher J., Liu, Qing, Bengmark, Stig, Bihari, David and Visvanathan, Kumar (2007) ‘Synbiotic-associated improvement in liver function in cirrhotic patients: Relation to changes in circulating cytokine messenger RNA and protein levels’, Microbial Ecology in Health and Disease, 19:1, 7 - 16

To link to this article: DOI: 10.1080/08910600601178709

URL: http://dx.doi.org/10.1080/08910600601178709

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.
ORIGINAL ARTICLE

Synbiotic-associated improvement in liver function in cirrhotic patients: Relation to changes in circulating cytokine messenger RNA and protein levels

STEPHEN M. RIORDAN1, NARELLE A. SKINNER2, CHRISTOPHER J. MCIVER3, QING LIU1, STIG BENGMARK4, DAVID BIHARI5 & KUMAR VISVANATHAN2

1Gastrointestinal and Liver Unit, Prince of Wales Hospital and University of New South Wales, Sydney, Australia, 2Department of Infectious Diseases, Monash Medical Centre and Monash University, Melbourne, Australia, 3Department of Microbiology, Prince of Wales Hospital and University of New South Wales, Sydney, Australia, 4Institute of Hepatology, University College London, UK and 5Department of Intensive Care, Prince of Wales Hospital and University of New South Wales, Sydney, Australia

Abstract

Background/Aims: Mechanisms by which synbiotic treatment improves liver function in patients with cirrhosis are unknown. This study was performed to address this important issue.

Patients and methods: Thirty cirrhotic patients were randomized to receive synbiotic or placebo preparations for 7 days. Viable faecal counts of Lactobacillus species, Child-Pugh class, plasma retention rate of indocyanine green (ICG_R15), whole blood tumour necrosis factor alpha (TNF-α) mRNA and interleukin-6 (IL-6) mRNA, serum TNF-α, soluble TNF receptor (sTNFR)I, sTNFRII and IL-6 and plasma endotoxin levels were measured pre- and post-treatment.

Results: Synbiotic treatment was associated with significantly increased faecal lactobacilli counts and significant improvements in ICG_R15 and Child-Pugh class. Significant increases in whole blood TNF-α mRNA and IL-6 mRNA, along with serum levels of sTNFRI and sTNFRII, also occurred. TNF-α and IL-6 levels correlated significantly, both at baseline and post-synbiotic treatment. Synbiotic-related improvement in ICG_R15 was significantly associated with changes in IL-6, both at mRNA and protein levels, and unrelated to plasma endotoxin values. No significant changes in any study parameter followed placebo treatment.

Conclusions: Short-term synbiotic treatment proven to modulate gut flora significantly improves liver function in patients with cirrhosis. Benefit is unrelated to reduction in endotoxaemia and may be mediated, at least in part, by treatment-related induction of IL-6 synthesis by TNF-α.

Key words: Cirrhosis, synbiotics, cytokines

Introduction

We have reported previously that short-term treatment with a synbiotic regimen comprising four different Gram-positive lactic acid bacterial species and bioactive fibres that alters the intestinal flora is associated with significant improvement in liver function in patients with cirrhosis, mostly due to hepatitis B virus or alcohol (1). A beneficial effect on hepatic function was subsequently reported with use of a probiotic preparation, comprising gut bacteria without supplementary fibre, in a cohort of patients with alcoholic cirrhosis (2). Mechanisms by which interventions to manipulate the gut flora may lead to improvement in liver function in patients with cirrhosis are currently uncertain.

Synbiotic treatment has been shown in patients with cirrhosis to increase peripheral blood monocyte expression of Toll-like receptor 2 (TLR2) (3), signaling via which likely contributes significantly to production of tumour necrosis factor-α (TNF-α) in this group (3). In addition, short-term exposure to the TNF-inducible cytokine, interleukin-6 (IL-6) (4), has been shown to reduce liver injury in experimental animal models of liver damage (5–14). Consequently, this study aimed to investigate whether the TNF-α/IL-6 cytokine pathway may
possibly contribute to the hepatoprotective effect of short-term synbiotic treatment seen clinically. To this end, we studied in our cirrhotic patients whole blood levels of TNF-α messenger RNA (mRNA) and IL-6 mRNA and serum levels of TNF-α, soluble TNF receptor I (sTNFRI; p55), soluble TNF receptor II (sTNFRII; p75) and IL-6, along with plasma levels of endotoxin, pre- and post-synbiotic or placebo treatment and correlated treatment-related changes in these parameters with changes in liver function, as reflected by the plasma clearance of indocyanine green (15,16) and Child-Pugh class (17).

**Patients and methods**

**Patients**
The study group included 30 outpatients attending a specialist liver clinic at a university teaching hospital with biopsy-proven cirrhosis due to a range of aetiologies and covering the spectrum of degrees of hepatic functional impairment as reflected by the Child-Pugh classification (17) (Table I). Patients were considered to have alcohol-related cirrhosis if alcohol intake had been in excess of 80 g/day in males and 30 g/day in females for more than 5 years and if testing for viral, metabolic and immune aetiologies was negative. Only patients who had been abstinent from alcohol for at least 3 months, as corroborated by family members and/or carers, were included, as alcohol influences the sensitivity of macrophages to endotoxin and the production of TNF-α (18,19). Patients with histological features of alcoholic hepatitis were excluded. Exclusion criteria also included a history within the previous 6 weeks of factors that may influence the intestinal flora (treatment with lactulose [β-galactofructosidase] or antibiotics), factors that may influence extra-intestinal translocation of gut flora and, hence, circulating endotoxin levels (primary intestinal disorders and gastrointestinal haemorrhage) and factors that may influence circulating cytokine levels (infection, immunomodulatory drug use and renal impairment (serum creatinine >120 μmol/L) (1,3). In addition to intermittent infection and gastrointestinal haemorrhage, patients with other possible causes of

**Table I. Clinical and demographic data in cirrhotic patients randomized to group A (synbiotic treatment) and group B (placebo treatment) and healthy controls.**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Cirrhosis: synbiotic-treated (group A)</th>
<th>Cirrhosis: placebo-treated (group B)</th>
<th>Healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>15</td>
<td>15</td>
<td>30</td>
</tr>
<tr>
<td>Median age (range) (years)</td>
<td>56 (36–70)</td>
<td>55 (42–73)</td>
<td>48 (32–68)</td>
</tr>
<tr>
<td>Aetiology of cirrhosis (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis C virus</td>
<td>7 (46.7)</td>
<td>7 (46.7)</td>
<td>–</td>
</tr>
<tr>
<td>Alcohol</td>
<td>6 (40.0)</td>
<td>7 (46.7)</td>
<td>–</td>
</tr>
<tr>
<td>Other</td>
<td>2 (13.3)</td>
<td>1 (6.7)</td>
<td>–</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
<td>1 (6.7)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Non-alcoholic steatohepatitis</td>
<td>1 (6.7)</td>
<td>1 (6.7)</td>
<td>–</td>
</tr>
<tr>
<td>Child-Pugh grade (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>6 (40.0)</td>
<td>5 (33.3)</td>
<td>–</td>
</tr>
<tr>
<td>B</td>
<td>5 (33.3)</td>
<td>7 (46.7)</td>
<td>–</td>
</tr>
<tr>
<td>C</td>
<td>4 (26.7)</td>
<td>3 (20.0)</td>
<td>–</td>
</tr>
<tr>
<td>Presence of ascites (%)</td>
<td>3 (20.0)</td>
<td>3 (20.0)</td>
<td>–</td>
</tr>
<tr>
<td>Median baseline parameters (range)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum bilirubin (μmol/L)</td>
<td>25 (7–66)</td>
<td>29 (12–79)</td>
<td>–</td>
</tr>
<tr>
<td>Serum albumin (g/L)</td>
<td>32 (21–40)</td>
<td>31 (23–38)</td>
<td>–</td>
</tr>
<tr>
<td>International normalized ratio</td>
<td>1.4 (1.0–1.7)</td>
<td>1.5 (0.9–1.9)</td>
<td>–</td>
</tr>
<tr>
<td>INR</td>
<td>38.3 (5.9–60.0)</td>
<td>31.0 (6.0–48.0)</td>
<td>–</td>
</tr>
<tr>
<td>Whole blood TNF-α mRNA*</td>
<td>0.10 (0.01–0.27)</td>
<td>0.13 (0.01–0.32)</td>
<td>0 (0–0.02)**</td>
</tr>
<tr>
<td>Whole blood IL-6 mRNA*</td>
<td>0.0013 (0.0001–0.0065)</td>
<td>0.0010 (0.0001–0.0052)</td>
<td>0 (0–0.0001)**</td>
</tr>
<tr>
<td>Serum TNF-α (pg/ml)</td>
<td>3.5 (0.6–7.7)</td>
<td>4.3 (0.5–7.0)</td>
<td>1.8 (&lt;0.5–3.5)**</td>
</tr>
<tr>
<td>Serum sTNFRI (pg/ml)</td>
<td>669 (285–1725)</td>
<td>743 (264–1812)</td>
<td>418 (133–1214)**</td>
</tr>
<tr>
<td>Serum sTNFRII (pg/ml)</td>
<td>829 (170–2839)</td>
<td>776 (170–2658)</td>
<td>379 (170–1947)**</td>
</tr>
<tr>
<td>Serum IL-6 (pg/ml)</td>
<td>3.0 (0.5–32)</td>
<td>3.4 (0.5–17)</td>
<td>0.7 (&lt;0.5–3.0)**</td>
</tr>
<tr>
<td>Detectable plasma endotoxin at baseline (%)</td>
<td>3/15 (20.0)</td>
<td>4/15 (26.7)</td>
<td>0/30 (0)**</td>
</tr>
</tbody>
</table>

Note that no clinical or demographic data differed significantly in group A and group B.

*Ratio to maximum value resulting from in vitro stimulation of PBMCs by endotoxin (10 μg/ml for 20 h).

**p ≤0.03 compared to both group A and group B.
reversible hepatic functional decompensation, such as drug-related hepatotoxicity and choleodocholithiasis, were excluded (1), as were those with iodine allergy, in whom administration of ICG is contraindicated. No change to any medical therapy was permitted during the period of study. No patient with hepatitis C virus-related cirrhosis received antiviral treatment prior to or during the study period.

Thirty asymptomatic volunteers of similar age and gender distributions to the cirrhotic group, with no history of liver disease, alcohol intake <20 g/day, normal liver function tests and no predisposition to altered gut flora, extra-intestinal translocation of gut flora or circulating cytokine levels, as above, served as controls (1,3), to establish normal ranges for whole blood TNF-α mRNA and IL-6 mRNA levels, serum TNF-α, IL-6, sTNFRI, sTNFRII levels and plasma endotoxin levels. Informed consent in writing was obtained from each patient. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the South Eastern Area Health Service Research Ethics Committee, Department of Health, New South Wales, Australia.

**Supplementation with the synbiotic regimen**

Coded sachets containing the study and placebo preparations (A, n=15 and B, n=15, respectively) were pooled. One sachet was randomly drawn from this pool for each patient at study entry. Patients drawn to receive treatment with sachets A (group A) received oral supplementation with a Gram-positive probiotic preparation consisting of four freeze-dried, non-urease-producing bacteria, namely *Pediococcus pentosaceus* 5-33:3, *Leuconostoc mesenteroides* 32-77:1, *Lactobacillus paracasei* subspecies *paracasei* 19 and *Lactobacillus plantarum* 2592, each at a dose of 10^9 colony forming units (cfu) per sachet, along with 10 g of bioactive, fermentable fibre (betaglucan, 2.5 g; inulin, 2.5 g; pectin, 2.5 g and resistant starch, 2.5 g) (Synbiotic 2000; Medipharm, Kagerod, Sweden). Patients drawn to receive treatment with sachets B (group B) received a non-fermentable placebo, namely crystalline cellulose (Medipharm) (1,3).

All patients in groups A and B received one sachet of the respective synbiotic or placebo preparation daily, taken in 150–200 ml of water, for 7 days. Patients in groups A and B were well-matched for clinical and demographic variables including age, gender, aetiology of cirrhosis, Child-Pugh classification and baseline ICG retention rate, whole blood TNF-α mRNA and IL-6 mRNA levels, serum TNF-α, IL-6, sTNFRI and sTNFRII levels and plasma endotoxin levels (Table I).

The identity of the contents of sachets A and B (synbiotic or placebo preparations) was unknown to the investigators until after the study had been completed and the results had been analysed, when the code was broken (1).

**Quantitative bacteriological analysis of faecal counts for viable counts of Lactobacillus species**

Faecal samples for determination of viable counts of *Lactobacillus* species, as a marker of effective colonization by bacteria included in the synbiotic preparation, were collected in sterile containers pre- and post-supplementation with the synbiotic and placebo preparations and cultured aerobically and anaerobically for 72 h. Representative bacterial colonies were identified to the genus level on the basis of their Gram stain reaction and colonial and cellular morphologies, as described previously (1). Viable faecal counts of *Lactobacillus* species were expressed as the logarithm of cfu per gram of dry faeces (1).

**Indocyanine green clearance**

Plasma disappearance of ICG was measured using an intravenous ICG dose of 0.5 mg/kg ideal body weight and a non-invasive transcutaneous system based on a finger-tip sensor and pulse densitometry (LiMon, Pulsson Medical Systems, Munich, Germany). The accuracy of this non-invasive method of determining ICG clearance has been validated in comparison to both serial blood sampling with consecutive spectrophotometric analyses and an intra-aortic fibreoptic technique (20,21). Pre- and post-treatment ICG clearance measurements were performed following a fast of at least 6 h and at the same time of day so as to eliminate any possible confounding effects of post-prandial and diurnal variations of portal vein flow, respectively. Results were expressed as percentage plasma retention of ICG at 15 min (ICGR15). The normal ICGR15 using this methodology in subjects without liver disease is <10% in our laboratory. The median (range) inter-assay variability of ICGR15 using our methodology, as assessed in eight healthy volunteers with normal liver function who received two intravenous ICG doses of 0.5 mg/kg body weight 2 h apart, was found to be 2.5% (0–3.6%).

**Blood sampling**

Peripheral blood was drawn using pyrogen-free needles, syringes and containers (Becton-Dickinson, Singapore). Whole blood was stored at −70°C until analysis within 6 weeks of collection. Where applicable, plasma and serum were separated in a refrigerated centrifuge at 4°C and stored at −70°C.
in pyrogen-free polyethylene cryotubes (Nunc, Denmark) until analysis – also within 6 weeks of collection.

Measurement of cytokine mRNA in whole blood
Total RNA was isolated from 250 μl whole blood, thawed on ice, with the addition of 750 μl triReagent LS (Molecular Research Center Inc., Cincinnati, OH, USA), 20 μl 5N acetic acid and 2 μl polycryl carrier (Molecular Research Center Inc.), according to the manufacturer's protocol. Total RNA was dissolved in 100 μl nuclease-free water (Promega Corp., Madison, WI, USA). A 25 μl aliquot of RNA was reverse transcribed using M-MuLV reverse transcriptase (USB Corp, Cleveland, OH, USA) and pd(N)₆ random primers (Amersham Pharmacia Biotech, Piscataway, NJ, USA) in a final reaction volume of 50 μl.

Real time PCR was performed using 2 μl of cDNA for amplification. Oligonucleotide primers used are listed in Table II (22,23). In all, 900 nM of each forward and reverse primer (Geneverworks, Adelaide, Australia) were used per 10 μl reaction. PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) in 384-well clear optical reaction plate (Applied Biosystems). Reaction conditions were 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 s at 95°C and 1 min at 60°C. Melt curve analysis was performed. No unspecific amplification products were observed. All PCR reactions were performed in triplicate. Threshold cycle numbers were determined with Sequence Detector Software (version 2.0, Applied Biosystems). Standard curves for quantification were constructed by establishing the maximum mRNA production by peripheral blood monocytes in response to stimulation with endotoxin (10 μg/mL for 20 h) in vitro and performing serial dilutions. TNF-α mRNA and IL-6 mRNA levels in study patients and control subjects were expressed as a ratio to maximum stimulation values.

Serum TNF-α assay
Serum TNF-α was measured using the Quantikine HS Human TNF-α Immunoassay (R&D Systems Inc., Minneapolis, USA), according to the manufacturer’s instructions. The sensitivity of the assay was 0.5 pg/ml.

Serum sTNFR assays
Serum sTNFRI (p55) and sTNFRII (p75) were measured using Quantikine HS Human sTNFR Immunoassays (R&D Systems Inc.), according to the manufacturer's instructions. The sensitivity of the sTNFRI and sTNFRII assays was 3.0 pg/ml and 1.0 pg/ml, respectively.

Serum IL-6 assay
Serum IL-6 was measured using the Quantikine HS Human IL-6 Immunoassay (R&D Systems Inc.), according to the manufacturer’s instructions. The sensitivity of the assay was 0.5 pg/ml.

Plasma endotoxin assay
Plasma endotoxin was measured using the chromogenic limulus amoebocyte lysate assay (Associate of Cape Cod Inc., MA, USA), according to the manufacturer’s instructions. The sensitivity of the assay was 3 pg/ml.

Statistical analyses
Statistical analyses were performed using the Mann–Whitney rank sum test, Spearman’s rank correlation test, the Wilcoxon rank sum test and Fisher’s exact test, as appropriate (Systat for Windows, version 5.02, Systat Inc., Evanston, IL, USA). The probability level of \( p \leq 0.05 \) was set for statistical significance.

Results
Viable faecal counts of Lactobacillus species pre- and post-symbiotic treatment
Symbiotic treatment was associated with a significant increase in viable faecal counts of Lactobacillus species (Figure 1, left). No significant change in faecal counts of Lactobacillus species occurred in placebo-treated patients (Figure 1, right).

Table II. Oligonucleotide primers used for real-time PCR analysis.

<table>
<thead>
<tr>
<th>cDNA</th>
<th>Forward</th>
<th>Reverse</th>
<th>Amplicon size</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>AGGCCTGGTCCTGTTCTGCTCA</td>
<td>GTTCGAGAGATGATCTGACTGCC</td>
<td>167 bp</td>
<td>22</td>
</tr>
<tr>
<td>IL-6</td>
<td>GTTACATCTCCTGACGCGCATCT</td>
<td>GTGCCTCTTGTGCTGCTTAC</td>
<td>81 bp</td>
<td>23</td>
</tr>
</tbody>
</table>
ICG clearance and Child-Pugh class pre- and post-synbiotic treatment

Baseline ICG$_{R15}$ was abnormal ($\geq$10%) in 14/15 (93.3%) of cirrhotic patients randomized to treatment with the synbiotic preparation and in 14/15 (93.3%) of those randomized to treatment with the placebo preparation (Figure 2).

Synbiotic treatment was associated with a significant improvement in ICG clearance, with a median reduction in ICGR$_{15}$ compared with baseline values of 15.2% (range 4.4–65.0%) occurring in 14/15 (93.3%) patients (Figure 2, left). No significant change in ICGR$_{15}$ followed treatment with the placebo (Figure 2, right).

Improvement in Child-Pugh classification occurred in 4/9 (44.4%) patients who were initially Child-Pugh class B or C and who were treated with the synbiotic preparation (from class B to class A: $n=2$; from class C to class B: $n=2$) and in 0/10 (0%) such patients treated with the placebo ($p = 0.03$). ICG clearance improved in all four synbiotic-treated patients in whom an improvement in Child-Pugh status was documented, as well as in 10/11 (90.9%) patients in whom the Child-Pugh grade remained stable during the period of the study.

The improvement in Child-Pugh classification in initially decompensated synbiotic-treated patients resulted from significant improvements in serum bilirubin and albumin concentrations and in the prothrombin time, expressed as the international normalized ratio (INR) (Figure 3a, b and c). No significant change in serum bilirubin or albumin levels or in the INR occurred in placebo-treated patients. No deterioration in Child-Pugh class occurred in any patient during the 7 day study period.

The synbiotic regimen was well tolerated with no change in general clinical condition. Two (13.3%) synbiotic-treated patients transiently complained of increased flatulence during the first few days of treatment.

Whole blood cytokine mRNA levels pre- and post-synbiotic treatment

Baseline whole blood TNF-α mRNA and IL-6 mRNA levels were each significantly higher in cirrhotic patients randomized to synbiotic or placebo treatment than in healthy controls, but did not differ significantly between the treatment groups (Table I).

Synbiotic treatment was associated with further significant increases in both TNF-α mRNA (Figure 4) and IL-6 mRNA (Figure 5) levels, with post-treatment values increased in comparison to baseline levels by a median of 11.1% (range 4.4–65.0%) and 70.0% (range 23.1%–500%), respectively.

No significant change in either TNF-α mRNA or IL-6 mRNA levels occurred in placebo-treated patients ($p > 0.3$).

Serum cytokine levels pre- and post-synbiotic treatment

Baseline serum TNF-α, sTNFRI, sTNFRII and IL-6 levels were each significantly higher in cirrhotic patients randomized to synbiotic or placebo treatment than in healthy controls, but did not differ significantly between the treatment groups (Table I).

Synbiotic treatment was associated with further significant increases in serum sTNFRI and sTNFRII levels (Figures 6 and 7), with post-treatment values increased in comparison with baseline values by a median of 56.6% (range 52.7%–177.6%) and a
median of 42.2% (range -79.8% to 836.0%), respectively. Post-treatment serum IL-6 values were increased by a median of 100% (range 8.3-1500%) in 10/15 (66.7%) patients and reduced by a median of 87% (range 43-93%) in the remaining 5 (33.3%) patients ($p=0.25$). Serum TNF-$\alpha$ levels were increased by a median of 77% (range 10-133%) in 5/15 (33.3%) patients and reduced by a median of 35% (range 4-80%) in the other 10 (66.7%) patients ($p=0.19$).

No significant change in serum TNF-$\alpha$, sTNFRI, sTNFRII or IL-6 levels occurred in placebo-treated patients ($p>0.30$).

**Correlations between circulating cytokine and endotoxin levels in synthbiotic-treated patients**

Baseline circulating IL-6 values were significantly correlated with TNF-$\alpha$ values, both at mRNA and protein levels, in keeping with the known role of TNF-$\alpha$ in inducing production of IL-6 (4). The degree of change in IL-6 following synthbiotic treatment, expressed as the percentage change compared with baseline values, also correlated significantly with the degree of change in TNF-$\alpha$, both at mRNA and protein levels (Table IV).
Baseline plasma endotoxin values did not correlate significantly with levels of whole blood TNF-α mRNA or IL-6 mRNA or serum levels of TNF-α, sTNFRI, sTNFRII or IL-6. Similarly, the degree of change in plasma endotoxin concentrations following synbiotic treatment, expressed as the percentage change compared with baseline values, did not correlate significantly with the degree of change in any of these parameters ($r < 0.20, p > 0.30$).

**Discussion**

This report documents significant improvement in liver function in patients with cirrhosis, mostly due to chronic hepatitis C viral infection or alcohol, who underwent short-term treatment with a synbiotic preparation shown to significantly modulate the gut flora. In particular, enhanced clearance of ICG occurred in $>90\%$ of treated patients, accompanied by improvement in the Child-Pugh class in nearly 50\% of those initially categorized as Child-Pugh class B or C. Instances of improvement in Child-Pugh class resulted from modest yet statistically significant improvements in laboratory indices including the serum bilirubin and albumin concentrations and the INR. No deterioration in Child-Pugh class occurred in any synbiotic-treated patient. It is unlikely that the improvement in liver function seen in our synbiotic-treated patients was simply the consequence of improved clinical monitoring during the study period, as no significant change in ICG clearance or improvement in Child-Pugh class occurred in placebo-treated patients in our study, despite comparable baseline clinical and demographic profiles and clinical follow-up schedules. The degree of improvement in ICG clearance in synbiotic-treated patients in our study, although also only modest on occasion, was nonetheless sufficient to promote significant changes in the faecal flora of our patients.

We sought to identify possible mechanisms by which synbiotic treatment may lead to improved liver function in cirrhotic patients, focusing in particular on the possible importance of the TNF-α/IL-6 cytokine cascade. Notably, highly significant correlations were apparent between baseline IL-6
and TNF-α levels, both at the protein and mRNA levels, in the cirrhotic patients enrolled in our study, in keeping with the known effect of TNF-α in inducing IL-6 synthesis (4). We found evidence of up-regulation of the TNF-α/IL-6 pathway following symbiotic treatment, with significantly increased whole blood TNF-α mRNA and IL-6 mRNA levels and serum sTNFRI and sTNFRII concentrations compared with baseline occurring in symbiotic-treated but not in placebo-treated patients. As at baseline, the extent of changes in circulating IL-6 and TNF-α values following symbiotic treatment were significantly correlated at both mRNA and protein levels, suggesting that the increased IL-6 expression following symbiotic treatment is also TNF-α-induced.

The degree of improvement in ICG clearance that followed symbiotic treatment in our cirrhotic patients was significantly correlated with the magnitude of treatment-associated increases in circulating IL-6, both at protein and mRNA levels, raising the possibility that this pleiotropic cytokine may at least contribute to the hepatoprotective effect of symbiotic therapy in this setting. Recent experimental data support this concept. In particular, IL-6 has been shown in experimental animals to protect against liver injury induced by carbon tetrachloride (5), alcohol (6), ischaemia/reperfusion (7), Fas (8), concanavalin A (9), haemorrhagic shock (10) and following liver transplantation, including that involving steatotic donor organs (11,12). Recent experimental studies indicate that mechanisms of benefit of IL-6 include both pro-regenerative and anti-apoptotic effects on hepatocytes, evident within a few days of IL-6 exposure (13,14), with this rapid onset of benefit of particular interest in view of our finding in this report of clinical benefit within 7 days of commencement of symbiotic treatment and associated increased whole blood IL-6 mRNA expression. Protection against sinusoidal cell necroapoptosis resulting in augmentation of the hepatic microcirculation has also been documented (12). Further studies in suitable experimental animal models, including IL-6 knockout mice in comparison to wild-type animals, will clarify to what extent and by what exact mechanisms IL-6 may promote the hepatoprotective effect of symbiotic treatment in cirrhosis.

TNF-α and IL-6 are cleared by the liver (24,25) and cross-sectional analyses have shown that circulating levels are highest in those cirrhotic patients with more advanced degrees of hepatic dysfunction, implying that hepatic metabolism substantially influences the peripheral blood levels found clinically (26). We speculate that enhanced hepatic clearance of TNF-α and IL-6 consequent to improved liver function following symbiotic treatment, counter-balancing treatment-related increases in cytokine production, might account for our finding that the significant increases in TNF-α and IL-6 at the mRNA level associated with symbiotic supplementation were not replicated at the protein level. It is notable that significant increases in serum levels of sTNFRI and sTNFRII were documented following symbiotic treatment, providing further evidence of up-regulation of the TNF-α pathway in this circumstance.

Endotoxin, an essential cell wall component of Gram-negative bacteria, is an important cause of liver damage in experimental animals (27–29) and we have previously documented that elevated circulating endotoxin levels in patients with cirrhosis are significantly reduced following symbiotic treatment (1). Our findings in this study, however, suggest that reduction in endotoxaemia is not necessary for symbiotic treatment-associated improvement in hepatic function to occur. Plasma endotoxin levels were elevated at baseline in only a minority of our study cohort and ICG clearance improved both in patients with initially undetectable plasma endotoxin levels and in those in whom the plasma endotoxin concentration remained elevated despite symbiotic treatment. Conversely, ICG clearance failed to improve in the only symbiotic-treated patient with

Table III. Correlations between degrees of improvement in ICGR15 and other study parameters, expressed as percentage increase or decrease compared to baseline values, in symbiotic-treated patients.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>r</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole blood TNF-α mRNA</td>
<td>0.24</td>
<td>0.38</td>
</tr>
<tr>
<td>Serum TNF-α</td>
<td>0.26</td>
<td>0.36</td>
</tr>
<tr>
<td>Serum sTNFRI</td>
<td>0.40</td>
<td>0.14</td>
</tr>
<tr>
<td>Serum sTNFRII</td>
<td>0.38</td>
<td>0.16</td>
</tr>
<tr>
<td>Whole blood IL-6 mRNA</td>
<td>0.68</td>
<td>0.006</td>
</tr>
<tr>
<td>Serum IL-6</td>
<td>0.64</td>
<td>0.01</td>
</tr>
<tr>
<td>Plasma endotoxin</td>
<td>0.27</td>
<td>0.32</td>
</tr>
</tbody>
</table>

Bold font denotes statistical significance.
initially elevated plasma endotoxin whose plasma endotoxin concentration fell below the level of detection post-treatment. We could not postulate a role for endotoxaemia in promoting TNF-α or IL-6 production in our patients, as no significant correlation was apparent between circulating endotoxin and either TNF-α or IL-6, either at mRNA or protein levels, at baseline or following synbiotic supplementation. These findings are in keeping with our earlier reported observation that signaling via TLR4, the endotoxin receptor, is unlikely to contribute significantly to circulating TNF-α and sTNFR levels in cirrhotic patients (3).

We conclude that short-term use of a synbiotic regimen proven to modulate the gut flora significantly improves liver function in patients with cirrhosis. This beneficial effect is not dependent upon reduction in endotoxaemia and may be mediated, at least in part, by treatment-related induction of IL-6 synthesis by TNF-α.

References

